Clinical studyAcute and sustained effects of dihydropyridine-type calcium channel antagonists on oxidative stress in systemic sclerosis☆
Section snippets
Sample
We included consecutive patients with systemic sclerosis who had been hospitalized for systematic follow-up. Patients were classified as having limited or diffuse cutaneous disease (18). We excluded patients who could not stop vasodilator therapy, as well as those who were pregnant or current smokers, or who had diabetes, hypercholesterolemia, or severe disease (e.g., cardiac or hepatic failure, cancer, or gangrene). We also excluded patients who had not been stable on their current treatment
Results
We included 42 successive systemic sclerosis patients (38 [90%] women; mean [± SD] age, 54 ± 12 years). All patients had Raynaud's phenomenon (Table 1). The control group of 23 healthy subjects included 20 (87%) women, with a mean age of 49 ± 10 years. Of the 19 patients included in the long-term evaluation, 16 (84%) were women; they had a mean age of 58 ± 12 years and a mean disease duration of 8 ± 8 years, and 12 (63%) had limited cutaneous disease.
Discussion
Our data demonstrate excessive oxidative stress in patients with systemic sclerosis after cessation of dihydropyridine treatment (at baseline). In addition, we found a substantial acute and sustained decrease in oxidative stress after treatment with a dihydropyridine.
We chose different markers to explore different aspects of oxidative stress. Carbonyl residues are well-accepted markers of protein oxidation, whereas advanced oxidation protein products have been validated more recently. In our
References (29)
- et al.
Monocytes of patients with systemic sclerosis (scleroderma) spontaneously release in vitro increased amounts of superoxide anion
J Invest Dermatol
(1999) - et al.
Oxidative damage to proteinsspectrophotometric method for carbonyl assay
Methods Enzymol
(1994) - et al.
Advanced oxidation protein products as a novel marker of oxidative stress in uremia
Kidney Int
(1996) - et al.
Improved methods to measure end products of nitric oxide in biological fluidsnitrite, nitrate and S-nitrosothiols
Nitric Oxide
(1997) - et al.
Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosis
Toxicology
(2000) - et al.
Further evidence of increased polymorphonuclear cell activity in patients with Raynaud's phenomenon
Br J Rheumatol
(1992) - et al.
Abnormalities of erythrocyte membrane fluidity, lipid composition, and lipid peroxidation in systemic sclerosisevidence of free radical-mediated injury
Arthritis Rheum
(2000) - et al.
Oxidative stress in systemic sclerosis
Mol Cell Biochem
(1999) - et al.
Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma
Arthritis Rheum
(1996) - et al.
Increased urinary F2-isoprostanes in systemic sclerosis, but not in primary Raynaud's phenomenoneffect of cold exposure
Arthritis Rheum
(2002)
Oxidative stress in sclerodermamaintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway
Arthritis Rheum
Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidations reactionsimplications for pathogenesis
J Exp Med
Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis
J Rheumatol
A double-blind placebo-controlled trial of anti-oxidant therapy in limited cutaneous systemic sclerosis
Clin Exp Rheumatol
Cited by (0)
- ☆
This work was partly supported by a grant from Association des Sclérodermiques de France.